关键词：Blisibimod，A-623，系统性红斑狼疮，红斑狼疮研究，BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor，Q9Y275
一 、产品描述
Blisibimod (A 623) 是一种有效和选择性的四价B细胞激活因子(BAFF)抑制剂。Blisibimod可用于系统性红斑狼疮(SLE)的研究。
二 、抗体详情
Research Grade Blisibimod
|
靶点 |
BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
|
货号 |
DHJ85305 |
|
形态 |
Liquid |
|
纯度 |
>95% as determined by SDS-PAGE. |
|
同型 |
Fusion - [peptide 16-mer - peptide 19-mer]2 - IGHG1 Fc (Fragment constant) |
|
应用 |
Research Grade Biosimilar |
|
别名 |
A-623 |
|
表达系统 |
Mammalian Cells |
|
注意 |
仅供科研使用 |
三、 已发表文献
|
Update on clinical trials in systemic lupus erythematosus. PMID: 27314466 |
|
Biotherapies in systemic lupus erythematosus: New targets. PMID: 27663753 |
|
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. PMID: 28331294 |
|
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. PMID: 24748629 |
佰乐博生物作为法国AntibodySystem在亚洲的总代理商，提供近30,000种生命科学试剂，核心产品涵盖蛋白、抗体和试剂盒，旨在为科研工作者提供专业、全面、可靠的试剂支持，推动生命科学研究的深入发展。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：info@biolabreagent.com
